in patients with cocaine-associated chest pain who do not have evidence of ischemia or cardiovascular complications, but there is no study in literature assessing the cost benefit and readmission rate of IT vs. NIT in patients with CICP admitted to the hospital. Methods: Retrospectively data of 83 consecutive patients from 2002-2010 who were admitted with CICP with positive urine drug screen was analyzed. Cost of admission of each patient was calculated by including cost of hospital stay, medications, laboratory tests, EKG, cardiac stress test and left heart catheterization. IT arm included patients who underwent left heart catheterization (LHC), NIT arm included patients managed conservatively (with or without stress test). Medical records of these patients were followed for 2 years to look at the number of readmissions for CICP. A Man-Whitney U test was calculated to compare cost in the IT vs. NIT. A Chi-square test was done, to compare the incidence of readmissions between the two groups. Results: Among patients with CICP, 17 patients underwent IT, 66 patients were managed conservatively (NIT). Overall, average length of stay was 2.7 days and cost of hospitalization was $5336.54. Man-Whitney U test revealed that the total hospitalization cost in the IT group (M-placeϭ69.24) was significantly higher (Uϭ98.000, pϽ0.001) than the NIT group (M-placeϭ34.98). Median cost in IT group was $8626.06 vs. $3674 in NIT group. 16 patients had at least one readmission in 2 years. Overall, there were 41 re-admissions (Average 0.59 readmissions per person in 2 years). There was no significant difference in the number of readmission between the IT and NIT groups [Chi-square (DFϭ1) 1.108, pϭ0.293] Conclusion: Patient admitted with CICP who were managed conservatively had lower cost of management and similar number of readmissions compared to subjects who were managed invasively. Conservative management can be preferred in patients with CICP.
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The Background: Historically, women with cardiovascular (CV) disease have more comorbidities and a higher risk for major CV events and death than men. Outcomes following percutaneous coronary intervention with new generation drug-eluting stents suggest this disparity between sexes is decreasing. Nevertheless, there are clear biological differences between men and women that impact the risk for CV events. Long-term outcomes following treatment with the Resolute™ zotarolimus-eluting stent (R-ZES) have not been reported according to sex. Methods: Patient-level data was pooled from RESOLUTE All Comers (Nϭ1140), RESOLUTE (Nϭ139), RESOLUTE US (Nϭ1402), RESOLUTE-International (Nϭ2349) and RESOLUTE-Japan (Nϭ100) and stratified by sex. Two-year safety endpoints were compared between the groups after propensity score adjustment for differences in baseline characteristics. Endpoints include cardiac death, target-vessel myocardial infarction (TV-MI), clinically-driven target lesion revascularization (TLR), target-lesion failure (TLF; composite of cardiac death, TV-MI and TLR) and definite/ probable stent thrombosis (ST) through 2 years. All RESOLUTE trials prescribed at least six months dual antiplatelet therapy. Results: There were 3,842 men and 1,288 women evaluated. Men were younger (62.8 vs 66.9 yrs, pϽ.001), less likely to have diabetes (27.2% vs 38.0%, pϽ.001) and more like to have had a prior MI (28.5% vs 20.3%, pϽ.001). Men had longer lesions (15.9 vs 15.1 mm, pϭ.001) a larger pre-procedure diameter stenosis (75.9% vs 74.3%, pϽ.001). At 2 years there was no significant difference in any endpoint between the sexes. TLF was 9.0% for men vs 10.2% for women; cardiac death plus TV-MI was 5.0% in men and 6.6% in women. Rates of late and very late ST were 0.2% and 0.1% for men and 0.2% for women at both timepoints. Conclusions: When adjusted for baseline differences in clinical and lesion characteristics, there was no increase in CV events among women treated with R-ZES compared with men. At 2 years after R-ZES treatment, event rates were low and similar for both men and women. 
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Conclusion:
In this cohort of patients, iodinated contrast dye allergy was not associated with the development of renal dysfunction at 3 months after diagnostic angiography or percutaneous intervention or of long-term development of end-stage renal disease requiring dialysis. The association between dye allergy and reduced mortality needs to be confirmed in a larger cohort.
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Radiation Dose During Coronary Angiography: Correlation To Body Mass Index 
Glan Clwyd Hospital, Bodelwyddan, United Kingdom
Introduction: Coronary angiography (CAG) is a commonly performed procedure in cardiology, resulting in patients being exposed to radiation. Patients with high body mass index (BMI) are at increased risk of coronary artery disease. Catheter laboratory intensifiers use automatic exposure control (AEC) which adjusts radiation dose aiming to provide optimal quality images. Factors shown to be responsible for dose variability are complexity of the procedure, operator experience, their level of training in radiation protection, type and performance of x-ray equipment. The objective of present study was to evaluate if radiation dose received by patients correlated with BMI. Method: Retrospective data for 3678 CAG performed from Sep-07 to Mar-10 from a single centre, were analysed. Radiation dose was calculated as Dose Area Product (DAP) in mGym 2 .
Results: Mean radiation dose during the procedure was 4339 Ϯ 286 mGym 2 . Mean BMI, contrast volume used and screening time were 29.22 Ϯ 0.08 kg/m2, 125 Ϯ 10.0 ml and 5.2 Ϯ 0.1 minutes respectively. BMI was positively correlated with increasing radiation dose during CAG (graph-1 & 2). Patients with increased BMI did not require prolonged procedure or increased contrast volume. There was no significant inter-operator variability. Even Ten degree increase in angulation (oblique, cranial or caudal) increased radiation dose significantly. Conclusion: Patients with increased BMI receive a significantly higher radiation dose during CAG, affecting not only the patient, but every one present in the catheter laboratory. This has to be recognized by the operator when undertaking procedures in patients with a high BMI. N S , V O L . 6 , N O . 2 , S u p p l S , 2 0 1 3 
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